Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Autros Acquisition, Guardian Software May Boost Baxter Public Safety Image

This article was originally published in The Gray Sheet

Executive Summary

Recent patient safety-related measures taken by Baxter International may help improve the firm's public image after a series of recalls and warning letters related to Baxter dialyzers and infusion pumps

You may also be interested in...



Baxter dialyzers

Planned closure of the firm's Ronneby, Sweden and Miami Lakes, Florida plants, which made recently discontinued A-series hemodialyzer components, is announced Nov. 26. The Swedish filter plant and the Florida filter fiber facility employed 158 and 98 people, respectively. A small team will remain at both locations to continue ongoing investigations into more than 50 deaths worldwide that appear linked to a processing fluid residue ("The Gray Sheet" Nov. 12, 2001, p. 16). Baxter has agreed to pay the families of 10 fatalities in Spain $289,000 each under a settlement agreement; the families are asking the Spanish government to drop a planned lawsuit. A Swedish criminal investigation is ongoing...

Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

UsernamePublicRestriction

Register

MT015800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel